Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifaximin - Alfasigma

Drug Profile

Rifaximin - Alfasigma

Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; L-105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD; Rifaximin-a 550mg; rifaximin-alpha; Rifxima; SLX-G1043; SLX-G1063; SLX-L1042; SLX-L1044; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; Zaxine

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Alfasigma; ASKA Pharmaceutical; Bausch Health Companies; Lupin; Norgine; Salix Pharmaceuticals; University of Washington; Yokohama City University
  • Class Anti-infectives; Anti-inflammatories; Antianaemics; Antibacterials; Antidiarrhoeals; Hepatoprotectants; Irritable bowel syndrome therapies; Rifamycins; Skin disorder therapies; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Hepatic encephalopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
  • Phase III Crohn's disease; Liver disorders
  • Phase II Intestinal obstruction; Rosacea; Sickle cell anaemia
  • Phase Unknown COVID 2019 infections
  • No development reported Unspecified
  • Discontinued Bacterial vaginosis; Clostridium difficile infections; Pouchitis; Shigella infections

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in New Zealand (PO, Capsule)
  • 04 Sep 2023 Bausch Health Americas completes a phase II trial in Sickle cell anaemia (In adults, In the elderly) in USA, Canada, Kenya (PO) (NCT05098028)
  • 17 May 2023 US district court upholds final judgment for rifaximin that prevents FDA approval of Norwich's ANDA until 2029
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top